In this issue, Carpio and colleagues1 report on a randomised, double blind, placebo controlled trial on patients with neurocysticercosis (see page 1050). Their findings, published on behalf of the Ecuadorian Neurocysticercosis Group, add to the vividly debated issue of treatment of neurocysticercosis.2 Albendazole treatment was evaluated to reduce active brain cysts of neurocysticercosis and seizure recurrence. Carpio and colleagues1 found that in significantly more patients, active brain cysts were cured and a higher reduction of number of brain cysts was achieved. These findings confirm previous reports. However, although a significant reduction in brain cysts …